Advanced Brain Monitoring

Advanced Brain Monitoring occupies a specialized position at the intersection of neurodiagnostics, sleep medicine, medical devices, and clinical research. Its differentiation is breadth across the measurement workflow: Sleep Profiler systems capture EEG and other physiological signals in home settings, B-Alert X-Series supports cognitive-state and human-factors research, STAT X-Series addresses portable neurological assessment, and Night Shift Therapy applies positional monitoring to obstructive sleep apnea treatment. The company also combines hardware with automated sleep staging, biomarker analysis, reporting, and clinical-trial support. This gives it a different profile from narrower sleep-device vendors or software-only EEG analytics companies. Its approximately 51–100 employee scale and $2.34 million in disclosed funding suggest a focused specialist rather than a heavily capitalized platform company. The reported 27 granted patents further support technical defensibility, although commercial adoption and revenue scale remain unclear.

Advanced Brain Monitoring has followed a long, research-driven development path since its 1997 founding. The company raised $836,778 in a venture round on Apr 7, 2009 and later received a $1.5 million NIDA grant on Oct 2, 2019, bringing disclosed funding to $2,336,778 across two rounds. Its trajectory has centered on converting multi-sensor neuroscience expertise into portable products: Sleep Profiler and Sleep Profiler PSG2 target in-home, multi-night sleep assessment; Night Shift Therapy applies monitoring to positional sleep apnea treatment; and B-Alert and STAT X-Series extend the platform into cognitive research and neurological assessment. The November 2023 launch of a wireless 24-channel EEG system integrated with Stratus EEG cloud software marks a meaningful expansion toward hospital and home seizure monitoring. A current search for a Clinical Research Manager indicates continued investment in trial execution and neuroscience programs, while the absence of reported layoffs supports operational continuity. Growth should be interpreted cautiously because public evidence of revenue, customer expansion, employee growth, and post-2023 launches is limited.